All News

Top news of the day from across the health care landscape.

The approval is based on data from 2, phase 3 studies, AMBER and EMERALD, which evaluated the safety and efficacy of Symtuza compared with a control regimen in adults with no prior antiretroviral (ARV) history and in virologically suppressed adults.

This is the first approval that the FDA has granted as part of its new approaches to streamlining the development and review of oncology drugs.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.

Study finds that specialty drug coverage policies are mostly inconsistent across health plans and many treatments have multiple restrictions to access.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The phase 3 CAPSTONE-2 study of the safety and efficacy of baloxavir marboxil in patients at high risk of complications due to influenza (flu) has met the primary objective of efficacy of a single dose of baloxavir marboxil compared to placebo.

New research has identified the origins of acute myeloid leukemia, which can be detectable more than 5 years before the disease develops.

Health care providers who offer HIV tests encourage patients to integrate preventive screenings into their health care routines.

Although resistance can be attributed to many different causes, inappropriate prescribing is arguably one of the main contributors.

The phase 3 randomized, double-blind study evaluated a single dose of baloxavir marboxil compared with placebo and oseltamivir in individuals aged 12 and older.

Individuals treated for cancer in adolescence or young adulthood may be at higher risk for endocrine diseases, such as thyroid disease, testicular dysfunction, and diabetes.

Most individuals with multiple sclerosis experience pain as a symptom of the disease.

The FDA is alerting health care professionals and patients of a voluntary recall of several, but not all, drug products containing the active ingredient valsartan.

The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

A new study provides insight into previously unknown details about the capsid that may have implications for the development of new drugs to treat the infection.

The CDC and FDA are currently investigating a multistate outbreak of Cyclospora infections (cyclosporiasis) linked to McDonald’s salads.

Officials with the US FDA are alerting health care professionals and patients of a voluntary recall of several, but not all, drug products containing the active ingredient valsartan.

Enzalutamide (Xtandi) is the first and only FDA-approved oral medication for both non-metastatic and metastatic castration-resistant prostate cancer.

Officials with the FDA have approved tecovirimat (TPOXX, SIGA), the first drug with an indication for the treatment of smallpox, to boost preparedness in the event of a bioterror attack

Study suggests that covering high-value medications benefits patients at no extra cost to insurers.

Although eradicated in 1980 due to vaccination efforts, there have been concerns of the virus being used as a potential weapon in bioterrorism.

Tecovirimat (TPOXX, SIGA) is the first drug with an indication for the treatment of smallpox.

Researchers aim to determine whether an annual brain volume loss rate of less than 0.4% is a valid marker to assess treatment response.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.